ArticleJACC. Cardiovascular imaging2011
Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study.
Article in JACC. Cardiovascular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
200 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Beyond Angiography: Integrating Advanced Diagnostic Modalities in Coronary Stent Restenosis-a Systematic Review.International journal of medical sciences · 2026Pooled it
- Automated Coronary Optical Coherence Tomography Feature Extraction with Application to Three-Dimensional Reconstruction.Tomography (Ann Arbor, Mich.) · 2022Pooled it
- Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies.BMC medicine · 2015Pooled it
- Outcomes of Patients With High-Risk Plaques Treated With a Bioresorbable Magnesium Scaffold: Insights From the BIOMAG-I Study.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Trial
- Discordance in the diagnostic assessment of vulnerable plaques between radiofrequency intravascular ultrasound versus optical coherence tomography among patients with acute myocardial infarction: insights from the IBIS-4 study.The international journal of cardiovascular imaging · 2021Trial
- Pre-Emptive OCT-Guided Angioplasty of Vulnerable Intermediate Coronary Lesions: Results from the Prematurely Halted PECTUS-Trial.Journal of interventional cardiology · 2020Trial
- High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD: Insights From the PROMISE Trial.JACC. Cardiovascular imaging · 2019Trial
- Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology.Cardiovascular diabetology · 2017Trial
- Oscillatory wall shear stress is a dominant flow characteristic affecting lesion progression patterns and plaque vulnerability in patients with coronary artery disease.Journal of the Royal Society, Interface · 2017Trial
- Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study.Cardiovascular ultrasound · 2013Trial
- Beyond Angiography: Redefining The Gold Standard for Coronary Atherosclerosis.Current cardiology reports · 2026Review
- Non-invasive identification of high-risk plaques in non-culprit lesions of acute coronary syndrome.Heart and vessels · 2026Article
- From anatomy to vulnerability: A comprehensive appraisal of coronary physiology and plaque characterization.American heart journal plus : cardiology research and practice · 2026Review
- Integrated Coronary CT Angiography Assessment of Plaque Vulnerability and Clinical Outcomes: The Morphology-Inflammation-Burden (MIB) Score.JACC. Cardiovascular imaging · 2026Article
- Pathological mechanisms and research progress of multilevel intervention therapy for coronary heart disease.Frontiers in immunology · 2026Review
- Impact of low-density lipoprotein cholesterol-lowering therapy on intermediate stenosis in non-culprit vessels of acute coronary syndrome.BMC cardiovascular disorders · 2025Article
- Targeting Vulnerable Plaques in Coronary Artery Disease: Detecting Risk, Preventing Events.Current cardiology reports · 2025Review
- Intravascular Imaging Guidance for Percutaneous Coronary Interventions.Journal of clinical medicine · 2025Review
- Artificial Intelligence-Led Whole Coronary Artery OCT Analysis; Validation and Identification of Drug Efficacy and Higher-Risk Plaques.Circulation. Cardiovascular imaging · 2025Article
- From Vision to Illumination: The Promethean Journey of Optical Coherence Tomography in Cardiology.Journal of clinical medicine · 2025Review
140 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
objectivesThe purpose of this study was to determine whether thin-capped fibroatheromata (TCFA) identified by virtual histology intravascular ultrasound (VH-IVUS) are associated with major adverse cardiac events (MACE) on individual plaque or whole patient analysis.
backgroundPost-mortem studies have identified TCFA as the substrate for most myocardial infarctions. However, little is known about the natural history of individual TCFA and their link with MACE. VH-IVUS provides a method of identifying plaques in vivo that are similar (although not identical) to histologically defined TCFA, and has been validated in human atherectomy and post-mortem studies.
methodsOne hundred seventy patients with stable angina or troponin-positive acute coronary syndrome referred for percutaneous coronary intervention (PCI) were prospectively enrolled and underwent 3-vessel VH-IVUS pre-PCI and also post-PCI in the culprit vessel. MACE consisted of death, myocardial infarction, or unplanned revascularization.
resultsIn all, 30,372 mm of VH-IVUS were analyzed. Eighteen MACE occurred in 16 patients over a median follow-up of 625 days (interquartile range: 463 to 990 days); 1,096 plaques were classified, and 19 lesions resulted in MACE (13 nonculprit lesions and 6 culprit lesions). Nonculprit lesion factors associated with nonrestenotic MACE included VHTCFA (hazard ratio [HR]: 7.53, p = 0.038) and plaque burden >70% (HR: 8.13, p = 0.011). VHTCFA (HR: 8.16, p = 0.007), plaque burden >70% (HR: 7.48, p < 0.001), and minimum luminal area <4 mm(2) (HR: 2.91, p = 0.036) were associated with total MACE. On patient-based analysis, the only factor associated with nonrestenotic MACE was 3-vessel noncalcified VHTCFA (HR: 1.79, p = 0.004).
conclusionsVH-IVUS TCFA was associated with nonrestenotic and total MACE on individual plaque analysis, and noncalcified VHTCFA was associated with nonrestenotic and total MACE on whole-patient analysis, demonstrating that VH-IVUS can identify plaques at increased risk of subsequent events. The preservation of the association between VHTCFA and MACE despite various analyses emphasizes its biological importance.
Indexed as
Identifiers
21835382What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.